ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Fakultet for naturvitenskap og teknologi
  • Institutt for kjemi
  • Artikler, rapporter og annet (kjemi)
  • View Item
  •   Home
  • Fakultet for naturvitenskap og teknologi
  • Institutt for kjemi
  • Artikler, rapporter og annet (kjemi)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

Permanent link
https://hdl.handle.net/10037/16738
DOI
https://doi.org/10.3324/haematol.2012.068890
Thumbnail
View/Open
article.pdf (242.2Kb)
Publisher's version (PDF)
Date
2013-05
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Lange, Thoralf; Ernst, Thomas; Gruber, Franz; Maier, Jacqueline; Cross, Michael; Müller, Martin C.; Niederwieser, Dietger; Hochhaus, Andreas; Pfirrmann, Markus
Abstract
The BCR-ABL T315I mutation causes resistance to imatinib, nilotinib and dasatinib in chronic myeloid leukemia. Forty BCR-ABL positive patients with imatinib resistance were analyzed for T315I mutated clones after six months on nilotinib or dasatinib treatment by quantitative allele-specific ligation polymerase chain reaction with a sensitivity of 0.05%. Ligation polymerase chain reaction revealed 10 patients with more than 10−5 BCR-ABLT315I%/GUS (high levels), none of whom achieved major molecular response after 12 months, and a further 8 patients with 10−5 or below BCR-ABLT315I%/GUS (low levels) who all achieved major molecular response (P<0.001). A second independent group showed molecular response in one of 12 patients with high levels and 5 of 8 patients with low levels (P=0.018). Combining the groups resulted in a sensitivity and specificity of 92.9% and 87.5%, respectively. We conclude that the quantitative level of mutant T315I allele is predictive of major molecular response at 12 months on second-line nilotinib or dasatinib treatment.
Description
Source at https://doi.org/10.3324/haematol.2012.068890.
Publisher
Ferrata Storti Foundation
Citation
Lange T, Ernst T, Gruber F, Maier J, Cross, Müller, Niederwieser D, Hochhaus A, Pfirrmann. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica. 2013;98(5):714-717
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (kjemi) [565]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)